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IntroduCtIon
Ensuring the long-term safety and effective-
ness of medical devices is critical to public 
health. Collecting outcomes through regis-
tries has exposed some high-profile failures 
of implanted devices, such as metal-on-metal 
hip prostheses.1 Well-established registries 
exist in many countries and more are being 
developed. Recently, the US Food and Drug 
Administration (FDA) began supporting 
registry-based efforts to expand the current 
infrastructure for recording the real-world 
performance of medical devices.2–5 However, 
the utility of registry-based active surveil-
lance for detecting safety signals and effi-
cacy concerns is by no means certain. Do 
they collect the key outcomes most likely to 
identify problems? Do they accrue sufficient 
numbers of patients to detect underper-
forming devices? Do they receive and review 
patient outcomes at appropriate intervals 
after implantation of devices? They need to 
produce relevant information in a timely way 
to help regulators and clinicians recognize 
devices with safety problems quickly. The 
data they provide can also help device manu-
facturers develop better next-generation 
products.
In this Analysis, we focus on four high-risk 
and widely used implanted medical devices: 
total hip replacement (THR) and total knee 
replacement (TKR) devices, stent grafts 
for endovascular aneurysm repair (EVAR), 
and surgical mesh implanted for pelvic 
organ prolapse (POP). We review evidence 
on device performance and analyze the 
likely numbers of patients whose data need 
to be recorded to detect a device which is 
performing significantly worse than expected. 
We review the current capacity of registries’ 
active surveillance and the supporting infra-
structure to conduct these analyses.
Long-term aCtIve devICe surveILLanCe and 
the roLe of regIstrIes
Many questions about the long-term safety 
and effectiveness of medical devices remain 
unanswered at the time of a device’s approval 
by a regulatory agency, because of the time 
required to gather sufficient data (especially 
data on long-term performance) and the high 
costs associated with data collection. An agreed 
plan for real-world long-term active surveil-
lance can reduce preapproval data collection 
burden and give patients earlier access to new 
and safe technologies. The balance between 
preapproval and postapproval data collection 
required by regulatory agencies (eg, FDA) is 
gradually shifting.6 Traditionally, long-term 
active surveillance of device safety has relied on 
adverse event reports that physicians, health-
care institutions, manufacturers, and patients 
submit to the FDA and to regulators in other 
countries, and on regulator-required postap-
proval studies that manufacturers conduct. 
However, previous research has demonstrated 
the shortcomings of postapproval studies7 and 
adverse event reports: these include under-re-
porting and lack of denominator data to 
conduct population-level adverse event esti-
mates.7 8
Registries offer a promising alternative or 
adjunct: they have exposed serious device-re-
lated problems in the past and recent reports 
have highlighted their potential.9–11 Linkage 
of registries and creation of coordinated 
registry networks (CRN) are likely to become 
an important method for tracking patient 
outcomes and assessing the performance of 
devices.
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Table 1 Summary and background for three measures chosen for each of the four devices
Measure chosen Description
Total hip/knee replacement
  Harris Hip Score/Knee Society Score  ► Harris Hip Score (HHS) is a clinician-administered survey based on a 100-point scale to assess 
hip pain and function after surgery.
 ► Knee Society Score (KSS) is a validated 200-point scale to assess knee condition after surgical 
intervention.
  QoL  ► Patient-reported physical, social and mental functioning using the Short Form 12 (SF-12) and 
Short Form 36 (SF-36).
  Revision  ► A reoperation due to mechanical or biological failure.
 ► Used as safety indicator registries.36–39
 ► Widely accepted as a patient-centered outcome.
Endovascular aneurysm repair (EVAR)
  Endoleak  ► Continued perfusion and pressurization.
 ► Considered as an effectiveness outcome.40 41
 ► 20%–25% of EVAR procedures are complicated by endoleaks.42 43
 ► Excluding type II, the cumulative endoleak rate is 5.67% at 2 years.26
  30-day all-cause mortality  ► Most frequently used primary outcome in major clinical trials such as EVAR 1, EVAR 2 and 
ACE.44–47
 ► Mortality varies from 0.5% to 3.6%48 based on different studies and different EVAR grafts.40 41 49
  Secondary vascular intervention  ► Major indications: endoleak, graft migration, kinking of limb grafts, stenosis and occlusions, and 
landing site enlargement.50
 ► Reintervention rates are 17% for intermediate follow-up (up to 4 years) and 23% for a longer 
term follow-up (beyond 4 years) with a median of 6 years.51
Surgical mesh for POP
  QoL  ► King’s College Pelvic Organ Prolapse Quality of Life (P-QoL)27–29 is the most commonly used 
validated questionnaire with nine domains.
  Total reoperation rate  ► Reoperation due to postoperative complications and prolapse recurrence.
 ► Total 1-year reoperation rate is estimated to be 3%–4%.30–32
 ► Estimates for longer term (1.5–5 years) vary between 8.5% and 13%.52 53
  Mesh erosion  ► One of the most frequently experienced safety issues related to vaginal mesh is the risk of 
vaginal-urethral erosion/extrusion.
 ► Factors contributing to erosion include operative technique, implant size, and the specific 
properties of the material (size, stiffness, elasticity and basic tissue compatibility, and so on).54
 ► 110 studies based on safety warning, issued by FDA in 2011: approximately 10% of women 
undergoing POP repair with mesh experienced mesh erosion within 1 year.17 55
FDA, Food and Drug Administration; POP, pelvic organ prolapse.
foCus on partICuLar hIgh-rIsk ImpLanted devICes
We chose four types of implanted devices as test cases, 
which are in frequent use and for which registries and 
CRNs are being developed, to track their performance:
 ► THR and TKR—as two separate device categories: Total 
joint replacement (TJR), both hip and knee, is the 
fastest growing elective device-based surgery world-
wide. In the USA, over 400 000 hip and 610 000 knee 
replacements are performed annually, with combined 
numbers projected to reach 6 million by 2030.12–14
 ► EVAR: Abdominal aortic aneurysm (AAA) repair 
occurs more frequently in the USA (278 921) 
compared with the UK (29 300) during 2005–2012 
yet aneurysm-related death is three times more likely 
in the UK compared with the USA.15 Aneurysms were 
traditionally treated by inserting a synthetic graft in 
a major open surgery, but now the most common 
approach is via a significantly less invasive endovas-
cular procedure with a stent graft: this is EVAR. In 
2012, over 30 000 EVAR procedures were performed 
in the USA.16
 ► Surgical mesh for POP: Surgical mesh is often used in 
POP repair. In 2010, an estimated 300 000 POP repairs 
were completed in the USA.17 There are current 
concerns about the safety of these procedures: 1 in 
11 women experienced problems with vaginal mesh 
implants in the UK according to National Health 
Service (NHS) data on 92 000 women from Hospital 
Episodes Statistics.18
For each type of device, we selected three primary 
outcome measures to assess the performance of each 
device. The choice of outcomes was based on the most 
commonly collected key data items, related to safety, effec-
tiveness and/or patient-reported outcomes and are summa-
rized in table 1.
do regIstrIes enroLL suffICIent number of patIents?
The number needed to follow (NNF) is the number of 
patients a registry needs for a specific brand/type/class of 
device, to detect statistically significantly (p<0.05) worse 
performance compared with a prespecified threshold. 
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Appropriate choice of the threshold and of follow-up time 
for each device and outcome combination, used in our anal-
ysis, is described in more detail below. Operationally, the 
threshold for binary outcomes was a gold standard event 
rate and for continuous outcomes was a mean baseline 
or preoperative score. Then, the probability of detecting 
a significant departure from this gold standard or statis-
tical power was calculated. For binary outcomes, this was a 
one-side test of proportions using the formula:
 
Power = 1− β = 1− Φ
(√
n
(
p0−p1
)√
p1
(
1−p1
) + z1−α
√
p0
(
1−p0
)
p1
(
1−p1
)
)
 
where n = NNF,  p1  is the device performance rate and  p0  
is the gold standard performance rate,  Φ
(
.
)
  is the standard 
normal cumulative distribution function,  za  =  ath quantile 
of a standard normal distribution, α = significance level and 
 1− β  = power. Power for a generic binary outcome (table 2) 
was calculated for 1.5 times increased odds of underper-
forming compared with a gold standard performance 
rate per recommendations.19 For continuous outcomes, 
the power was computed for a one-sided alternative in a 
generalized estimating equations framework with a quasis-
core-based test statistic20 assuming only one group, a linear 
effect of time and a range (0.05–0.50) of intraclass correla-
tion coefficient, a parameter that accounts for correlations 
among repeated measures. Power for a generic continuous 
outcome (table 3) was calculated by considering small to 
moderate departures (0.3–0.5 SD) in the scale of Cohen’s 
d which is recommended for quality and patient-reported 
outcomes.21 22
Of note, these computations do not reflect missed 
follow-up measures, the rates of which vary widely with 
respect to procedures and outcomes. Our recommenda-
tion is to inflate NNF by appropriate context-dependent 
expected missing rates in the planning stage and in the 
analysis stage using statistical methods for ascertainment 
bias correction due to missing data such as robust or doubly 
robust methods (eg, inverse probability weighting or 
augmented inverse probability weighting) or use multiple 
imputation.23 Another important caveat is that our calcu-
lations do not account for subgroup analysis requirements 
(eg, hip implants performance in men and women sepa-
rately) and the NNF needs to be adjusted if such subgroup 
comparisons are planned in advance.
at what tIme poInts shouLd regIstrIes evaLuate devICe 
performanCe?
The number of times a device is evaluated is conceptual-
ized in two ways—‘one look’, when performance evalua-
tion is performed at the end of a specified time period 
(eg, 30 days for 30-day mortality); and ‘multiple looks’ 
when performance evaluation is performed repeatedly at 
several time intervals (eg, 1, 5 and 10 years). While the 
choice of time intervals is guided by narrative review of 
literature, they are presented for illustrative purposes 
only and our methodology can be adopted for any choice 
of time point. Critically, however, the overall type I error 
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Table 3 Sample size table for generic continuous outcome.
ICC Power Cohen's d
One look 
Long-term follow-up with multiple looks
1 year 5 years 10 years
n n n n
0.05 0.8 0.3 131 187 167 151
0.25 0.8 0.3 104 147 132 119
0.5 0.8 0.3 69 98 88 80
0.05 0.9 0.3 181 246 220 198
0.25 0.9 0.3 143 194 173 157
0.5 0.9 0.3 96 130 116 105
0.05 0.8 0.5 47 68 60 55
0.25 0.8 0.5 38 53 48 43
0.5 0.8 0.5 25 36 32 29
0.05 0.9 0.5 66 89 79 72
0.25 0.9 0.5 52 70 63 57
0.5 0.9 0.5 35 47 42 38
Rows correspond to various levels of power, intraclass correlation coefficient (ICC) and effect size (measured by Cohen’s d). Columns 
provide sample size for one look or assessment and continual monitoring with multiple looks or assessments at 1, 5 and 10 years. The 
type I error for ‘one look’ is controlled at 5% and for ‘multiple looks’ is jointly controlled at 5% using Bonferroni’s method.
or alpha, in every situation, should be controlled at 5% 
and adjusted for multiple looks, at certain time inter-
vals, using a simple and conservative method such as 
Bonferroni’s method (as we use here) or other alpha-
spending methods such as O’Brien-Fleming, Pocock or 
Lan-DeMets.
what IndICates that a devICe Is not performIng as 
expeCted?
The expected performance of devices at each follow-up 
time point was guided by a narrative review of litera-
ture (see online supplementary tables 1-4). When avail-
able (eg, endoleak endpoint after AAA) we gave priority 
to estimated thresholds from studies that conducted 
meta-analysis or meta-regression. In other instances, our 
estimated performance thresholds are conservative and 
a formal systematic review or meta-analysis is unlikely to 
change the results substantially.
hip and knee replacement
Key outcomes were scores of physical function, quality of 
life (QoL) measures and revision rates. Our assessment of 
Harris Hip Score (HHS) showed that following a cohort of 
341 patients will provide >90% power to detect an under-
performing device with a clinically meaningful change of 
4.5 HHS points (or d=0.3) after 5 and 10 years (table 4). 
Similarly, our assessment for Knee Society Score showed 
that a cohort of 341 patients is required to provide >90% 
power to detect an outlier device with a clinically mean-
ingful change of 4.5 points (or d=0.3) at the end of 5 and 
10 years.
Postoperative Short Form 12 (SF-12) is the most 
commonly used measure of general QoL. Using SF-12 
we found that a cohort of 181 (66) patients is needed to 
identify a small (moderate) change of 1.4 (2.4) points for 
THR or 1.6 (2.7) points for TKR, for ‘one look’ at the end 
of 1 year with 90% statistical power.
Based on National Institute for Health and Care Excel-
lence guidelines,24 rates of revision surgery for joint 
replacements should be <5% at 10 years as a metric of 
good performance and is commonly assessed at years 
2, 5, and 10.25 Following up a cohort of 2500 patients 
for 5 years would have >90% power to detect 1.5 times 
increased odds of revision compared with the annualized 
revision rate of 0.5%.
endovascular aneurysm repair
Three key outcomes are 30-day mortality, occurrence of 
endoleaks, and the need for secondary interventions (for 
endoleaks and other complications associated with the 
stent graft). Thirty-day all-cause mortality varies between 
0.5% and 3.6% (see online supplementary table 3) with a 
best estimate around 2%. Following up a cohort of 2200 
patients would provide >90% power to detect 1.5 times 
increased odds of 30-day all-cause mortality compared 
with the performance goal of 2% mortality.
A recent meta-regression26 estimated the cumulative 
rate of endoleak (excluding type II) occurrence to be 
5.67% at 2 years or an annualized rate of 2.84%. A cohort 
of 1400 participants would provide >90% power to detect 
1.5 times higher odds of endoleak occurrence at the end 
of 2 and 5 years. However, our NNF estimate is 525 to 
detect 1.75 times higher odds with 80% power that is 
similar to that estimated in Kent et al’s study.26
Secondary vascular interventions are estimated to occur 
at an annual rate of 4% (online supplementary table 3). 
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Table 4 Number needed to follow (NNF) of three measures of four devices and a power of >90%
Measure chosen Gold standard
Acceptable change from gold 
standard
Time point(s) to 
assess at
Maximum
NNF*
Total hip/knee replacement
Harris Hip Score/Knee Society 
Score
Postoperative score at year 2 4 points or d=0.3 5 and 10 years 341
QoL Preoperative score THR: 1.4, 2.4 points or d=0.3, 0.5
TKR: 1.6, 2.7 points or d=0.3, 0.5
1 year 181
Revision Annual rate of 0.5% OR=1.5 5 and 10 years 2500
EVAR
Endoleak Annual rate of 2.8% OR=1.5 2 and 5 years 1400
30-day all-cause mortality 2% OR=1.5 30 days 2200
Secondary vascular intervention Annual rate of 4% OR=1.5 4 and 6 years 450
Surgical mesh for POP
Erosion 6% OR=1.5 1 year 800
QoL Preoperative score 8.6, 14.4 points or d=0.3, 0.5 1 year 181
Total reoperation rate 3%–4% OR=1.5 1 year 1500
The gold standard for continuous outcomes is based on a baseline measure (before surgery or 2 years after surgery) and that for binary 
outcomes is based on gold standard rates from literature or expert opinion.
*The maximum is over multiple scenarios of gold standards and time points.
EVAR, endovascular aneurysm repair; POP, pelvic organ prolapse; QoL, quality of life;THR, total hip replacement; TKR, total knee 
replacement; d, Cohen’s d.
With this performance goal, the NNF is 450 for 4 and 6 
years (see table 1) to have >90% power to detect 1.5 times 
increased odds of secondary vascular intervention.
surgical mesh for pop
Key outcomes are QoL measures, mesh erosion and need 
for reoperation. Effectiveness outcomes in published 
reports on mesh repair are typically based on QoL scores 
(P-QoL) before and after the procedure.27–29 Following 
up a cohort of 181 patients has >90% power to identify a 
clinically meaningful 8.6 point change in P-QoL for ‘one 
look’ at 1 year postoperatively.
Mesh erosion is an important safety endpoint, and 
a cohort of 800 women followed up for 1 year would 
provide >94% power to detect 1.5 times higher odds for 
erosion compared with an overall erosion rate of 6% (see 
online supplementary table 4).
The risk of reoperation following POP repair with mesh 
due to postoperative complication or prolapse recurrence 
was estimated to be 3%–4% within 1 year.30–32 A cohort of 
1500 patients would provide >90% power to detect 1.5 
times increased odds of reoperation.
are Current regIstrIes suffICIent?
Our analyses suggest that registries do not need to follow 
unrealistically large cohorts to identify outlier performance 
of types of devices (eg, metal-on-metal hip implants). We 
evaluated current registry infrastructure to identifying devi-
ations from expected performance of the devices consid-
ered using three objective criteria—whether the registry 
contains enough patient records, captures the relevant 
measures, and conducts enough longitudinal follow-up—
and found most registries either contain sufficient numbers 
of patients already or are expected to be so in future.
Specifically for hip and knee replacements, the Amer-
ican Joint Replacement Registry, Function and Outcomes 
Research for Comparative Effectiveness in Total Joint 
Replacement registry, the Kaiser-Permanente National 
Total Joint Replacement Registry, and the Michigan Arthro-
plasty Registry together have data on over 1 million TJRs 
annually but lack robust capture of functional and quality 
measures (eg, HHS, QoL). The US Vascular Quality Initia-
tive (VQI), launched by the Society for Vascular Surgery in 
2011, has over 350 participating centers across 46 US states 
and Ontario, and has collected data on over 32 200 AAA 
repairs and adequately captures key performance measures. 
The Pelvic Floor Disorders Registry, founded to support US 
FDA recommendations for increased monitoring of trans-
vaginal mesh use, began collecting data in late 2015 and is 
currently too new to conduct robust analyses.33
Of note, it is unclear if the current registries are suffi-
ciently large for each device brand (eg, DePuy metal-
on-metal implant) because such details are not always 
recorded and future efforts to harmonize definitions 
need to be undertaken. In such scenarios, device classes 
could be studied by combining multiple brands and types 
(eg, compare metal-on-metal with metal-on-ceramic hip 
replacement devices).
what are the obstaCLes to progress?
Conducting long-term active surveillance is not easy and 
incomplete follow-up can limit the usefulness of registry 
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data. This problem could be addressed by linking regis-
tries with other data sources (eg, insurance claims data 
in private health systems) that collect patient outcomes 
over extended periods of time (eg, efforts are underway 
to link the VQI with claims data resources,34 providing 
longer follow-up to evaluate secondary vascular interven-
tion and possibly endoleak occurrence after device use). 
In the USA, the FDA has proposed a new National Evalu-
ation System for Health Technology,3 which will integrate 
registries with claims data to provide long-term follow-up. 
This method is better suited for clinically measured safety 
or effectiveness outcomes (eg, revision surgery for joint 
replacement) than for patient-reported outcomes (eg, 
QoL) which requires direct data collection (eg, telephone 
interviews). In the UK, linkages with routinely collected 
NHS statistics, national mortality data and with the Clin-
ical Practice Research Dataset35 are important linkages 
for long-term data acquisition.
Incorporation of patient-reported outcomes into long-
term active device surveillance will remain a challenge, 
because registries, claims data, or electronic health 
records do not currently capture such outcomes. Registry 
organizers, manufacturers, and healthcare providers will 
all have a part to play in developing mechanisms to collect 
patient-reported outcomes.
the future
Advancing technology will enable increasing amounts of 
useful data to be collected by device registries. Electronic 
health records, smartphone apps and wearable devices 
will enable a range of information, including patient-re-
ported outcome measures, to be captured. Increasing 
capacity for data linkage offers huge potential, but this 
will need careful attention to its governance. International 
linkages will increase the power of information gathering, 
but will require attention to differing national data legis-
lative requirements. Manufacturer’s registries straddle 
national boundaries, but these need assurances of trans-
parency and unbiased oversight to provide confidence in 
their data. Clear plans for the use of registries when new 
devices are presented for regulatory approval will help 
shift the balance that is required between premarket and 
postmarket evidence. It will allow earlier access to new 
products while providing assurance of a mechanism to 
monitor performance. The data from registries will help 
manufacturers to develop ever safer and more effective 
devices for future use.
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